PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.43%
Revenue growth at 50-75% of MRVL's 15.82%. Martin Whitman would worry about competitiveness or product relevance.
9.99%
Gross profit growth under 50% of MRVL's 20.31%. Michael Burry would be concerned about a severe competitive disadvantage.
29.39%
EBIT growth below 50% of MRVL's 235.66%. Michael Burry would suspect deeper competitive or cost structure issues.
29.39%
Operating income growth under 50% of MRVL's 235.66%. Michael Burry would be concerned about deeper cost or sales issues.
29.08%
Net income growth under 50% of MRVL's 326.22%. Michael Burry would suspect the firm is falling well behind a key competitor.
33.33%
EPS growth under 50% of MRVL's 324.22%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
20.48%
Diluted EPS growth under 50% of MRVL's 324.22%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.56%
Share reduction while MRVL is at 0.48%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
5.70%
Diluted share count expanding well above MRVL's 1.08%. Michael Burry would fear significant dilution to existing owners' stakes.
0.56%
Dividend growth above 1.5x MRVL's 0.22%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-40.45%
Negative OCF growth while MRVL is at 109.72%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40.16%
Negative FCF growth while MRVL is at 106.90%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
104.35%
10Y revenue/share CAGR above 1.5x MRVL's 25.12%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
58.19%
Positive 5Y CAGR while MRVL is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
60.18%
Positive 3Y CAGR while MRVL is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
964.73%
Positive long-term OCF/share growth while MRVL is negative. John Neff would see a structural advantage in sustained cash generation.
152.62%
Positive OCF/share growth while MRVL is negative. John Neff might see a comparative advantage in operational cash viability.
109.07%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
186.92%
Net income/share CAGR above 1.5x MRVL's 31.06% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
87.97%
Positive 5Y CAGR while MRVL is negative. John Neff might view this as a strong mid-term relative advantage.
187.54%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
166.39%
10Y equity/share CAGR above 1.5x MRVL's 46.25%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
36.74%
Positive 5Y equity/share CAGR while MRVL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
17.70%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.80%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
23.14%
AR growth well above MRVL's 24.24%. Michael Burry fears inflated revenue or higher default risk in the near future.
32.23%
Inventory growth well above MRVL's 3.04%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.97%
Asset growth above 1.5x MRVL's 1.28%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
7.37%
BV/share growth above 1.5x MRVL's 0.96%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.07%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
1.16%
We increase R&D while MRVL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-1.26%
We cut SG&A while MRVL invests at 1.89%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.